These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17566047)

  • 21. Inflammatory bowel disease: what is new?
    Marteau P; Daniel F; Seksik P; Jian R
    Endoscopy; 2004 Feb; 36(2):130-6. PubMed ID: 14765310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating young adults with chronic diarrhoea in primary care.
    Chapman TP; Chen LY; Leaver L
    BMJ; 2015 Feb; 350():h573. PubMed ID: 25716699
    [No Abstract]   [Full Text] [Related]  

  • 23. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical study of the relationship between inflammatory bowel diseases and colorectal neoplasms.
    Zhao YJ; Yuan YZ
    J Dig Dis; 2009 May; 10(2):113-7. PubMed ID: 19426393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory bowel disease: a model of chronic inflammation-induced cancer.
    Yang GY; Taboada S; Liao J
    Methods Mol Biol; 2009; 511():193-233. PubMed ID: 19347299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.
    Söderlund S; Granath F; Broström O; Karlén P; Löfberg R; Ekbom A; Askling J
    Gastroenterology; 2010 May; 138(5):1697-703. PubMed ID: 20167217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calprotectin testing in the community.
    Wassell J
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):1-2. PubMed ID: 21273635
    [No Abstract]   [Full Text] [Related]  

  • 28. Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?
    Bernstein CN
    Gut; 2008 Sep; 57(9):1194-6. PubMed ID: 18719132
    [No Abstract]   [Full Text] [Related]  

  • 29. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk.
    Poullis A; Foster R; Shetty A; Fagerhol MK; Mendall MA
    Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):279-84. PubMed ID: 14973103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease.
    Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG
    Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer surveillance in inflammatory bowel disease: new molecular approaches.
    Risques RA; Rabinovitch PS; Brentnall TA
    Curr Opin Gastroenterol; 2006 Jul; 22(4):382-90. PubMed ID: 16760754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Measurement of calprotectin in faeces].
    Jahnsen J; Røseth AG; Aadland E
    Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cancer and inflammatory bowel diseases].
    Flourié B; Moussata D; Nancey S; Bonvoisin S; Benahmed M; Descos L
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Suppl):S104-11. PubMed ID: 12704304
    [No Abstract]   [Full Text] [Related]  

  • 34. Is the risk of inflammatory bowel disease-related colorectal carcinoma limited?
    Sprakes MB; Everett SM
    Am J Gastroenterol; 2011 May; 106(5):999; author reply 999-1000. PubMed ID: 21540902
    [No Abstract]   [Full Text] [Related]  

  • 35. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease.
    Røseth AG; Aadland E; Grzyb K
    Scand J Gastroenterol; 2004 Oct; 39(10):1017-20. PubMed ID: 15513345
    [No Abstract]   [Full Text] [Related]  

  • 37. Inflammation and colorectal cancer.
    Kraus S; Arber N
    Curr Opin Pharmacol; 2009 Aug; 9(4):405-10. PubMed ID: 19589728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.